Skip to contentG
Grace Therapeutics, Inc.
G
GRCEGrace Therapeutics, Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$4.16M-$4.16MN/M vs Q3 2024 EPS Diluted-$0.36-$0.36N/M vs Q3 2024 Operating Income-$3,704,000N/M Operating Cash Flowderived-$4,115,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR
ended Dec 31, 2024 · filed Feb 13, 2025 · 44 d after period end